Tag
Nitroduck, founded by plant synthetic biologists and iGEM Grand Prize winners, is launching a CRISPR-based crop design platform that delivers gene edits via pollen grains instead of stem cells, aiming to make any crop gene-editable and eventually obsolete pesticides by 2042.
Y Combinator highlights how engineering skills translate to founding startups, featuring Shivani Patel and Chris Markus of Layers Bio and BootLoop AI, both SpaceX alumni taking ideas from zero to one.
The FDA is moving to withdraw approval of Amgen's vasculitis drug Tavneos after evidence emerged that ChemoCentryx manipulated data in its pivotal trial, leading to a NEJM retraction and market removals in the EU and UK, while Amgen fights to keep the drug on the US market.
Biotech founder Gabriel Ocana Santero of Exin Therapeutics connected an AI agent to a robotic surgical rig, allowing Claude Sonnet 5 to autonomously perform a brain injection on a live mouse with epilepsy after Claude Opus 5.5 refused to carry out the procedure, showcasing AI's emerging role as an active participant in laboratory research.
@muni_bio 和 @onepot_ai 于七月联合举办 Ebolathon，团队在一天内设计出 140 个靶向 Bundibugyo 埃博拉病毒进入细胞的小分子，经合成与测试后获得 18.6% 的初步命中率，部分流程由 Modal 提供算力支持。
Superpower announces Superpower Peptides, a prescription peptide care service pairing clinician-prescribed peptides like BPC-157, TB-500 and MOTS-c with comprehensive blood testing, monitoring, and membership, with pre-orders open and shipping targeted for late November.
MIT Technology Review's daily newsletter covering GLP-1 drugs' link to rising eating disorders, a short story about self-aware cities, PFAS cleanup efforts, and the largest crypto hack in history at Binance.
一篇 MIT Technology Review 报道指出，全球厌食症和暴食症发病率在1990至2023年间上升71%，临床医生发现GLP-1减重药物正被部分患者滥用，可能加剧饮食失调问题。
The tweet describes Mithril, an extremely lean, virtually operated drug R&D company that has sustained its operations through a model of “one operator + extensive use of Claude AI + part-time consultants,” evolving into an experiment in how far an individual can advance a drug R&D company with the help of AI.
Anthropic acquired Mithril Medicine, a biotech company with only one full-time employee, which relies on Claude and part-time consultants to drive drug development and is seen as an early sample of AI changing the way biopharma is organized.
Elon Musk tweeted that breakthroughs across all fields are accelerating exponentially, quoting a post claiming a massive, under-reported shift in human biology driven by biotech advances.
Commentary arguing that as AI makes drug discovery cheap, clinical trials and patient biology data become the bottleneck, highlighting tech giants like Anthropic and OpenAI moving into AI-driven drug development and biotech acquisitions.
A Verge Optimizer column examines the red flags in the new laser-based diagnostics venture Haemanthus, dubbed 'Theranos 2.0,' as depicted in Nathan Fielder's documentary, offering guidance on spotting health-tech hype versus real science.
Anthropic used its Claude model in partnership with Divergence Labs to generate around 35,000 antibody designs in weeks, with some candidates outperforming Xolair at dislodging cell-bound IgE in lab tests, accelerating food allergy treatment research.
Anthropic acquired Mithril Medicine, a one-person biotech founded by Cody Tranbarger (aka @Prof_Oak_), to advance a 'Pipeline-in-a-Person' operating model using Claude to run multiple drug programs in parallel and scale AI across biopharma.
CZ comments on news that Anthropic is partnering with six organizations to accelerate drug development using Claude, launching drug discovery programs targeting rare childhood muscular dystrophy.
Anthropic reports using Claude in real drug programs at six companies and its own in-house discovery efforts, including muscular dystrophy work that could reach human trials by late 2028.
Anthropic's IPO filing tempers its ambitious claims about AI revolutionizing biology and drug discovery, acknowledging its lack of lab experience, regulatory hurdles, and the long timelines of drug development while still positioning biotech discovery as a core part of its business.
MIT Technology Review's daily newsletter covers Anthropic's newly filed IPO prospectus and what it reveals about the AI investment boom, alongside features on solid-state transformers for the power grid and research into exercise-in-a-pill medicines.
Merck and Moderna's Phase 3 INTerpath-001 trial showed their personalized mRNA vaccine Intismeran Autogene, combined with Pembrolizumab, cut melanoma recurrence or death risk by 42 percent, marking a potential shift in early-stage melanoma treatment.